A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

A New York City hospital system is slashing new-patient appointment times to 20 minutes from 40. That's dangerous, a ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

The rise in misconduct allegations is in part the result of a new era of “scientific sleuths” who comb through scientific ...

Australian researchers said that supervised diets with intermittent fasting were for children with serious health conditions, ...

Amid layoffs and a disintegrating share price, former investor darling Ginkgo Bioworks is trying out a new tack to find ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

WASHINGTON — Sen. Bill Cassidy (La.), a key Republican senator with seats on the chamber’s health and finance committees, ...

FDA cites Granules, a large Indian generic drug manufacturer, for tossing truckloads of important documents from a facility ...

STAT's podcast The Readout LOUD this week discusses cannabinoid receptor drugs in weight loss, what the Fed's rates cut might ...

A Senate committee voted to hold Ralph de la Torre, CEO of troubled Steward Health Care, in contempt. If the full Senate ...